Work

A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.8088

Authors: Joel W. Neal, Heather A. Wakelee, Josephine Louella Feliciano, Sarah B. Goldberg, Daniel Morgensztern, Millie Snigdha Das, Rebecca Suk Heist, Inga Tolin Lennes, Alona Muzikansky, Martin J. Edelman, Scott N. Gettinger, Lecia V. Sequist

Institutions: Stanford Cancer Institute, Stanford University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Yale University, Washington University in St. Louis, Palo Alto Veterans Institute for Research, Massachusetts General Hospital, UNM Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2777697602

Cites:

Cited by: 6

Related to: 10